Scarica l'app Stockscreener
49.09
1.76%
0.85
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BBIO Giù?
Forum
Previsione
Precedente Chiudi:
$48.24
Aprire:
$48.51
Volume 24 ore:
2.14M
Relative Volume:
0.72
Capitalizzazione di mercato:
$9.38B
Reddito:
$217.77M
Utile/perdita netta:
$-438.86M
Rapporto P/E:
-20.37
EPS:
-2.41
Flusso di cassa netto:
$-456.33M
1 W Prestazione:
-0.24%
1M Prestazione:
+5.64%
6M Prestazione:
+53.65%
1 anno Prestazione:
+104.03%
Intervallo 1D:
$47.37
$49.14
Intervallo di 1 settimana:
$42.09
$49.14
Portata 52W:
$21.72
$49.77
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Nome
Bridgebio Pharma Inc
Settore
Industria
Telefono
(650) 391-9740
Indirizzo
3160 PORTER DR., PALO ALTO, CA
Confronta BBIO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
49.09 | 9.22B | 217.77M | -438.86M | -456.33M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-30 | Ripresa | Raymond James | Outperform |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-07-14 | Iniziato | Jefferies | Buy |
| 2025-07-09 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-06-17 | Iniziato | Wolfe Research | Outperform |
| 2025-03-31 | Iniziato | Redburn Atlantic | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-10-03 | Iniziato | Oppenheimer | Perform |
| 2024-09-04 | Iniziato | Piper Sandler | Overweight |
| 2024-03-21 | Ripresa | Raymond James | Outperform |
| 2024-01-31 | Iniziato | BMO Capital Markets | Market Perform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-11-07 | Iniziato | Citigroup | Buy |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-07-18 | Downgrade | Jefferies | Buy → Hold |
| 2023-04-19 | Iniziato | Evercore ISI | Outperform |
| 2023-02-06 | Iniziato | Cowen | Outperform |
| 2021-12-27 | Reiterato | Mizuho | Buy |
| 2021-12-27 | Reiterato | SVB Leerink | Outperform |
| 2021-09-10 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-03-22 | Reiterato | Goldman | Buy |
| 2021-02-22 | Ripresa | JP Morgan | Overweight |
| 2021-02-09 | Ripresa | Goldman | Buy |
| 2021-01-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-10 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-25 | Iniziato | BofA/Merrill | Neutral |
| 2020-05-19 | Iniziato | BTIG Research | Buy |
| 2020-04-13 | Iniziato | H.C. Wainwright | Buy |
| 2020-02-19 | Iniziato | Mizuho | Buy |
| 2019-07-26 | Iniziato | Raymond James | Outperform |
| 2019-07-22 | Iniziato | BMO Capital Markets | Outperform |
| 2019-07-22 | Iniziato | Goldman | Buy |
| 2019-07-22 | Iniziato | JP Morgan | Overweight |
| 2019-07-22 | Iniziato | Jefferies | Buy |
| 2019-07-22 | Iniziato | Piper Jaffray | Overweight |
| 2019-07-22 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Bridgebio Pharma Inc Borsa (BBIO) Ultime notizie
BridgeBio Pharma Inc. Stock Approaches Key Moving Average [Market Performance Recap]Free Technical Analysis for Trade Confirmation - 선데이타임즈
BridgeBio Pharma director Homcy sells $13.9m in stock - Investing.com
How BridgeBio Pharma Inc. stock performs during market volatilityReal-Time Trade Breakout Scanner - newsyoung.net
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Q2 2025 Earnings Call Transcript - Insider Monkey
Skeletal Dysplasia Market Growth Analysis 2025-2030 Featuring BioMarin Pharma, BridgeBio Pharma, Ascendis Pharma, Ipsen, QED Therapeutics and Other Major Players - uk.finance.yahoo.com
Mizuho Securities Sticks to Its Buy Rating for BridgeBio Pharma (BBIO) - The Globe and Mail
BridgeBio Pharma Insider Sold Shares Worth $3,666,949, According to a Recent SEC Filing - 富途牛牛
BBOT Debuts as a Publicly Traded Company Focused on - GlobeNewswire
BridgeBio’s oncology spinout sticks with SPAC to land on Nasdaq - Endpoints News
BridgeBio Pharma Inc. Stock Approaches Key Moving AverageAI Driven Stock Trend Forecast Shows Momentum Shift - beatles.ru
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - 富途牛牛
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Released Its Second-Quarter Earnings: Here's What Analysts Think - simplywall.st
Scotiabank Keeps Their Buy Rating on BridgeBio Pharma (BBIO) - The Globe and Mail
A Quick Look at Today's Ratings for BridgeBio Pharma(BBIO.US), With a Forecast Between $57 to $62 - 富途牛牛
BridgeBio Pharma Reports Strong Q2 2025 Results - The Globe and Mail
BridgeBio Pharma Shares Plunge 8.94% as $620M Trading Volume Surges 126.94% to Top 500-Stock Volume Rankings Despite $110M Revenue Growth and 3,751 Prescriptions for Attruby - AInvest
BridgeBio Pharma 2025 Q2 Earnings Deepened Losses Amid Record Revenue Growth - AInvest
BridgeBio Pharma stock hits 52-week high at 48.74 USD By Investing.com - Investing.com Australia
BridgeBio Earnings: Attruby Ramp Supports Long-Term Growth Outlook - Morningstar
BridgeBio Pharma stock rating reiterated at Buy by TD Cowen on strong Attruby sales - Investing.com Canada
As competition heats up, BridgeBio's Attruby sales underwhelm Wall Street despite growth - Endpoints News
Nxera debuts an obesity pipeline; BridgeBio battles Alnylam for market share - BioPharma Dive
BridgeBio Becomes The Victim Of Its Own Success As Attruby Gathers Steam - insights.citeline.com
Bridgebio Pharma shares fall 8.86% in premarket after Q2 earnings miss and Trump's tariff announcement. - AInvest
Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics - The Manila Times
BridgeBio Pharma stock price target raised to $61 by Oppenheimer - Investing.com Nigeria
Helix Acquisition Corp. II Retains Over 60% of Trust Account After Redemptions in BridgeBio Oncology Therapeutics Deal, Securing $382 Million in Gross Proceeds. - AInvest
BridgeBio Oncology Lands Massive $382M SPAC Deal as Top Investors Back Cancer Drug Pipeline - Stock Titan
BridgeBio Pharma Beat Estimates With Strong Q2 Revenue Growth - Finimize
BridgeBio Pharma Plunges 12.21% Amid Factory Orders Drop - AInvest
BridgeBio Pharma: Q2 Earnings Snapshot - New Haven Register
BridgeBio Pharma Inc (BBIO) Q2 2025 Earnings Call Highlights: Record Revenue Surge and ... - Yahoo Finance
BridgeBio Pharma Inc (BBIO) Q2 2025 Earnings Call Highlights: Record Revenue Surge and ... By GuruFocus - Investing.com Canada
Transcript : BridgeBio Pharma, Inc., Q2 2025 Earnings Call, Aug 05, 2025 - MarketScreener
Earnings call transcript: BridgeBio Pharma sees revenue surge in Q2 2025 By Investing.com - Investing.com South Africa
Earnings call transcript: BridgeBio Pharma sees revenue surge in Q2 2025 - Investing.com
BridgeBio Pharma earnings missed by $0.20, revenue topped estimates - Investing.com South Africa
BridgeBio Pharma (BBIO) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
BridgeBio Pharma, Inc. SEC 10-Q Report - TradingView
Why BridgeBio Pharma's Q2 Revenue Beat Signals a Catalyst for Outperformance - AInvest
Earnings Flash (BBIO) BridgeBio Pharma, Inc. Reports Q2 Revenue $110.6M, vs. FactSet Est of $88.0M - MarketScreener
BridgeBio Earnings: Attruby Sales Surge to $71M with Major Phase 3 Results Coming Fall 2025 - Stock Titan
BridgeBio Pharma stock hits 52-week high at 48.74 USD - Investing.com
BridgeBio Pharma Inc (BBIO) Q2 2025: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
What makes BridgeBio Pharma Inc. stock price move sharplySkyrocketing returns - Jammu Links News
Is BridgeBio Pharma Inc. a growth stock or a value stockMaximize your returns with smart trade entries - Jammu Links News
How strong is BridgeBio Pharma Inc. company’s balance sheetConsistently high returns - Jammu Links News
Is it the right time to buy BridgeBio Pharma Inc. stockFree Stock Movement Tracking - Jammu Links News
How does BridgeBio Pharma Inc. generate profit in a changing economyBeginner Investor Watchlist For 2025 - Jammu Links News
Can volume confirm reversal in BridgeBio Pharma Inc.AI Forecast for Trending Stocks Indicates Upside - metal.it
Cantor Fitzgerald Remains a Buy on BridgeBio Pharma (BBIO) - The Globe and Mail
Bridgebio Pharma Inc Azioni (BBIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):